The clinical hold removes near-term upside catalysts for AARD. Monitor for FDA feedback and unblinded data readout — if data is negative, the stock could face further downside. Cash runway into mid-2027 provides some time but no revenue floor. Traders should expect high volatility on any regulatory or data updates.
Price Chart
Executive Summary
Aardvark Therapeutics announced the FDA placed a full clinical hold on its IND for ARD-101, covering the Phase 3 HERO trial and open-label extension in Prader-Willi Syndrome. The company will unblind accumulated data to assess next steps, while holding $91.2M in cash to fund operations into mid-2027. This is a severe setback for a clinical-stage biotech with ARD-101 as its sole pipeline asset.
Key Facts
- FDA placed a full clinical hold on ARD-101 IND, covering all ongoing studies including Phase 3 HERO trial (AVK-101-301) and OLE trial (AVK-101-302).
- Clinical hold follows a previously announced voluntary pause; no timeline for resolution provided.
- Aardvark intends to unblind HERO and OLE trial data to evaluate efficacy and safety for next steps.
- As of March 31, 2026, cash and equivalents totaled $91.2M, sufficient into mid-2027.
- 68 patients dosed in HERO trial and 19 in OLE trial as of February 27, 2026.
Financial Impact
Full clinical hold on sole pipeline asset (ARD-101) for PWS; $91.2M cash runway into mid-2027 provides limited buffer but no near-term revenue catalyst.
Risk Factors
- Full clinical hold may require additional clinical data or trial redesign before lifting, delaying program by years.
- Unblinded data could reveal safety or efficacy concerns that permanently end the ARD-101 program.
- With ARD-101 as the only pipeline asset, a program termination would leave Aardvark with no clinical-stage candidates.
- Cash burn without revenue could necessitate dilutive financing if hold persists beyond mid-2027.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3295315 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | 8-K | $1.39 $1.08 | ▼ −22.30% | ▼ −23.01% | $1.08 (−22.30%) |
Oct 22, 2026 4d ago | 8-K | $1.39 $1.08 | ▼ −22.30% | ▼ −23.01% | $1.08 (−22.30%) |
Oct 22, 2026 4d ago | Press Release | $1.39 $1.08 | ▼ −22.30% | ▼ −23.01% | $1.08 (−22.30%) |
Oct 8, 2026 18d ago | 3 | $4.76 $4.45 | ▼ −6.51% | ▼ −6.45% | $1.08 (−77.31%) |
Oct 8, 2026 18d ago | 8-K | $4.76 $4.45 | ▼ −6.51% | ▼ −6.45% | $1.08 (−77.31%) |
Aug 12, 2026 10w ago | Institutional Cluster | $6.57 $6.41 | ▲ +2.44% | ▲ +3.13% | $1.08 (+83.56%) |
Aug 11, 2026 10w ago | 8-K | $6.57 $6.41 | ▲ +2.44% | ▲ +3.13% | $1.08 (+83.56%) |
Aug 11, 2026 10w ago | Press Release | $6.57 $6.41 | ▲ +2.44% | ▲ +3.13% | $1.08 (+83.56%) |
Jun 11, 2026 19w ago | Institutional Cluster | $3.64 $3.90 | ▲ +7.14% | ▲ +6.60% | $1.08 (−70.33%) |
May 14, 2026 23w ago | Press Release | $4.57 $4.36 | ▲ +4.60% | ▲ +4.53% | $1.08 (+76.37%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers